Evidence map›Paper›PMID 42095101›Full record

ArticleRSC advances2026

Aerobic oxidative condensation for the synthesis of phenoxazinone and phenazine derivatives catalyzed by an iron-porphyrin complex with a pendant imidazole ligand.

Cheng Wang, Shuai-Chen Zhang, Jing Zhang, Ke Guo, Peng Sun

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Cheng WangState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700 People's Republic of China psun@icmm.ac.cn.
Shuai-Chen ZhangState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700 People's Republic of China psun@icmm.ac.cn.
Jing ZhangState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700 People's Republic of China psun@icmm.ac.cn.
Ke GuoState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700 People's Republic of China psun@icmm.ac.cn.
Peng SunState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700 People's Republic of China psun@icmm.ac.cn.ORCID https://orcid.org/0000-0003-0348-5405

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phenoxazinone and phenazine represent privileged

Identifiers

PMID42095101
PMCPMC13139906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.